Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

autologous anti-CD19/CD20/CD22 CAR T cells

A preparation of autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19), CD20 and CD22, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19/CD20/CD22 CAR T-cells target and bind to CD19, CD20 and CD22 expressed on the surface of certain tumor cells. This induces selective toxicity in tumor cells expressing these TAAs. CD19, CD20 and CD22 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-CD19/CD20/CD22 CAR-T cells
autologous CAR19.20.22 CAR T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search